Host factors involved in the replication of hepatitis C virus

Reviews in Medical Virology

Volumn 17, Issue 5, 2007, Pages 343-354

  Moriishi, Kohji ^a   Matsuura, Yoshiharu ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLOPHILIN B; CYCLOSPORIN A; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOPHILIN; SYNAPTOBREVIN;

APLYSIA; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RNA REPLICATION; UPREGULATION; VIRUS REPLICATION;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 34548783857     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.542     Document Type: Review

References (114)

1. Moriishi K, Matsuura Y. Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003; 14: 285-297.
2. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
6. Sakamoto H, Okamoto K, Aoki M, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 2005; 1: 333-337.
7. Ni ZJ, Wagman AS. Progress and development of small molecule HCV antivirals. Curr Opin Drug Discov Devel 2004; 7: 446-459.
8. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-17514.
9. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111-122.
10. Okamoto T, Nishimura Y, Ichimura T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 2006; 25: 5015-5025.
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
13. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9299.
14. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
15. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
16. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 4017-1026.
17. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-2843.
18. Hamill P, Jean F. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells. Biochemistry 2005; 44: 6586-6596.
19. Egger D, Wolk B, Gosert R, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-5984.
20. Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci USA 2004; 101: 13038-13043.
21. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974.
22. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996; 15: 12-22.
23. Hamamoto I, Nishimura Y, Okamoto T, et al. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol 2005; 79: 13473-13482.
24. Tu H, Gao L, Shi ST, et al. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology 1999; 263: 30-41.
25. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989; 337: 476-478.
26. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755-757.
27. Siekierka JJ, Staruch MJ, Hung SH, Sigal NH. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol 1989; 143: 1580-1583.
28. Rahfeld JU, Schierhorn A, Mann K, Fischer G. A novel peptidyl-prolyl cis/trans isomerase from Escherichia coli. FEBS Lett 1994; 343: 65-69.
29. Schiene-Fischer C, Habazettl J, Schmid FX, Fischer G. The hsp70 chaperone DnaK is a secondary amide peptide bond cis-trans isomerase. Nat Struct Biol 2002; 9: 419-424.
30. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
31. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73: 1067-1078.
32. Wiegers K, Rutter G, Schubert U, Grattinger M, Krausslich HG. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology 1999; 257: 261-274.
33. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853.
34. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004; 430: 569-573.
35. Caroni P, Rothenfluh A, McGlynn E, Schneider C. S-cyclophilin. New member of the cyclophilin family associated with the secretory pathway. J Biol Chem 1991; 266: 10739-10742.
36. Spik G, Haendler B, Delmas O, et al. A novel secreted cyclophilin-like protein (SCYLP). J Biol Chem 1991; 266: 10735-10738.
37. Allain F, Denys A, Spik G. Characterization of surface binding sites for cyclophilin B on a human tumor T-cell line. J Biol Chem 1994; 269: 16537-16540.
38. Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV. Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol 2000; 14: 1175-1186.
39. Cohen E, Taraboulos A. Scrapie-like prion protein accumulates in aggresomes of cyclosporin A-treated cells. EMBO J 2003; 22: 404-417.
40. Ishii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006; 80: 4510-4520.
41. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288.
42. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-572.
43. Lam E, Martin M, Wiederrecht G. Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. Gene 1995; 160: 297-302.
44. Edlich F, Weiwad M, Erdmann F, et al. Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin. EMBO J 2005; 24: 2688-2699.
45. Edlich F, Weiwad M, Wildemann D, et al. The specific FKBP38 inhibitor N-(N′,N′-dimethylcarboxamidomethyl)cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem 2006; 281: 14961-14970.
46. Nielsen JV, Mitchelmore C, Pedersen KM, Kjaerulff KM, Finsen B, Jensen NA. Fkbp8: novel isoforms, genomic organization, and characterization of a forebrain promoter in transgenic mice. Genomics 2004; 83: 181-192.
47. Bulgakov OV, Eggenschwiler JT, Hong DH, Anderson KV, Li T. FKBP8 is a negative regulator of mouse sonic hedgehog signaling in neural tissues. Development 2004; 131: 2149-2159.
48. Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 1993; 75: 1417-1430.
49. Chang DT, Lopez A, von Kessler DP, et al. Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development 1994; 120: 3339-3353.
50. Briscoe J, Ericson J. Specification of neuronal fates in the ventral neural tube. Curr Opin Neurobiol 2001; 11: 43-19.
51. Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 1996; 383: 407-413.
52. Chen Y, Struhl G. Dual roles for patched in sequestering and transducing Hedgehog. Cell 1996; 87: 553-563.
53. Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the Hedgehog receptor. Nature 1996; 384: 176-179.
54. Price MA, Kalderon D. Proteolysis of cubitus interruptus in Drosophila requires phosphorylation by protein kinase A. Development 1999; 126: 4331-4339.
55. Ohlmeyer JT, Kalderon D. Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator. Nature 1998; 396: 749-753.
56. Wijgerde M, McMahon JA, Rule M, McMahon AP. A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. Genes Dev 2002; 16: 2849-2864.
57. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277: 1109-1113.
58. Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003; 5: 28-37.
59. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci USA 2001; 98: 13931-13935.
60. Naito T, Momose F, Kawaguchi A, Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 2007; 81: 1339-1349.
61. Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 2002; 277: 45306-45314.
62. Burch AD, Weller SK. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J Virol 2005; 79: 10740-10749.
63. Kampmueller KM, Miller DJ. The cellular chaperone heat shock protein 90 facilitates Flock House virus RNA replication in Drosophila cells. J Virol 2005; 79: 6827-6837.
64. Connor JH, McKenzie MO, Parks GD, Lyles DS. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 2007; 362: 109-117.
65. Hu J, Toft DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J 1997; 16: 59-68.
66. Hu J, Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 1996; 93: 1060-1064.
67. Geller R, Vignuzzi M, Andino R, Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 2007; 21: 195-205.
68. Skehel PA, Martin KC, Kandel ER, Bartsch D. A VAMP-binding protein from Aplysia required for neurotransmitter release. Science 1995; 269: 1580-1583.
69. Nishimura Y, Hayashi M, Inada H, Tanaka T. Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem Biophys Res Commun 1999; 254: 21-26.
70. Skehel PA, Fabian-Fine R, Kandel ER. Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc Natl Acad Sci USA 2000; 97: 1101-1106.
71. Soussan L, Burakov D, Daniels MP, et al. ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles. J Cell Biol 1999; 146: 301-311.
72. Kagiwada S, Hosaka K, Murata M, Nikawa J, Takatsuki A. The Saccharomyces cerevisiae SCS2 gene product, a homolog of a synaptobrevin-associated protein, is an integral membrane protein of the endoplasmic reticulum and is required for inositol metabolism. J Bacteriol 1998; 180: 1700-1708.
73. Weir ML, Klip A, Trimble WS. Identification of a human homologue of the vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (VAP-33): a broadly expressed protein that binds to VAMP. Biochem J 1998; 333(Pt 2): 247-251.
74. Nelson GA, Ward S. Amoeboid motility and actin in Ascaris lumbricoides sperm. Exp Cell Res 1981; 131: 149-160.
75. Italiano JE Jr, Stewart M, Roberts TM. How the assembly dynamics of the nematode major sperm protein generate amoeboid cell motility. Int Rev Cytol 2001; 202: 1-34.
76. Roberts TM, Stewart M. Acting like actin. The dynamics of the nematode major sperm protein (msp) cytoskeleton indicate a push-pull mechanism for amoeboid cell motility. J Cell Biol 2000; 149: 7-12.
77. Tarr DE, Scott AL. MSP domain proteins. Trends Parasitol 2005; 21: 224-231.
78. Loewen CJ, Roy A, Levine TP. A conserved ER targeting motif in three families of lipid binding proteins and in Opilp binds VAP. EMBO J 2003; 22: 2025-2035.
79. Pennetta G, Hiesinger PR, Fabian-Fine R, Meinertzhagen LA, Bellen HJ. Drosophila VAP-33A directs bouton formation at neuromuscular junctions in a dosage-dependent manner. Neuron 2002; 35: 291-306.
80. Weir ML, Xie H, Klip A, Trimble WS. VAP-A binds promiscuously to both v- and tSNAREs. Biochem Biophys Res Commun 2001; 286: 616-621.
81. Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, Brunger AT. Structural basis of FFAT motif-mediated ER targeting. Structure 2005; 13: 1035-1045.
82. Brickner JH, Walter P. Gene recruitment of the activated INO1 locus to the nuclear membrane. PLoS Biol 2004; 2: e342.
83. Funakoshi T, Yasuda S, Fukasawa M, Nishijima M, Hanada K. Reconstitution of ATP- and cytosol-dependent transport of de novo synthesized ceramide to the site of sphingomyelin synthesis in semi-intact cells. J Biol Chem 2000; 275: 29938-29945.
84. Fukasawa M, Nishijima M, Hanada K. Genetic evidence for ATP-dependent endoplasmic reticulum-to-Golgi apparatus trafficking of ceramide for sphingomyelin synthesis in Chinese hamster ovary cells. J Cell Biol 1999; 144: 673-685.
85. Kawano M, Kumagai K, Nishijima M, Hanada K. Efficient trafficking of ceramide from the endoplas-mic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT. J Biol Chem 2006; 281: 30279-30288.
86. Quintavalle M, Sambucini S, Summa E, et al. Hepatitis C virus NS5 A is a direct substrate of CKI-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J Biol Chem 2007; 282: 5536-5544.
87. Neddermann P, Quintavalle M, Di Pietro C, et al. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 2004; 78: 13306-13314.
88. Burckstummer T, Kriegs M, Lupberger J, Pauli EK, Schmittel S, Hildt E. Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett 2006; 580: 575-580.
89. Gao L, Aizaki H, He JW, Lai MM. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 2004; 78: 3480-3488.
90. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol 2003; 77: 4160-4168.
91. Zhang J, Yamada O, Sakamoto T, et al. Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology 2004; 320: 135-143.
92. Amarilio R, Ramachandran S, Sabanay H, Lev S. Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction. J Biol Chem 2005; 280: 5934-5944.
93. Giese SI, Woerz I, Homann S, Tibroni N, Geyer M, Fackler OT. Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef. Virology 2006; 355: 175-191.
94. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Krausslich HG. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci USA 2006; 103: 2641-2646.
95. Mannova P, Fang R, Wang H, et al. Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics 2006; 5: 2319-2325.
96. Oomens AG, Bevis KP, Wertz GW. The cytoplasmic tail of the human respiratory syncytial virus F protein plays critical roles in cellular localization of the F protein and infectious progeny production. J Virol 2006; 80: 10465-10477.
97. Chen BJ, Takeda M, Lamb RA. Influenza virus hemagglutinin (H3 subtype) requires palmitoylation of its cytoplasmic tail for assembly: M1 proteins of two subtypes differ in their ability to support assembly. J Virol 2005; 79: 13673-13684.
98. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-2566.
99. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
100. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-1205.
101. Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007; 104: 1661-1666.
102. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004; 324: 450-461.
103. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-15870.
104. Wang C, Gale M Jr, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005; 18: 425-434.
105. Ilyin GP, Rialland M, Glaise D, Guguen-Guillouzo C. Identification of a novel Skp2-like mammalian protein containing F-box and leucine-rich repeats. FEBS Lett 1999; 459: 75-79.
106. Shimakami T, Honda M, Kusakawa T, et al. Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. J Virol 2006; 80: 3332-3340.
107. Goh PY, Tan YJ, Lim SP, et al. Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J Virol 2004; 78: 5288-5298.
108. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006; 80: 7199-7207.
109. Kawamura H, Govindarajan S, Aswad F, et al. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice. Hepatology 2006; 44: 936-944.
110. Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002; 196: 641-653.
111. Ogata H, Kobayashi T, Chinen T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006; 131: 179-193.
112. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067.
113. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-365.
114. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 1997; 94: 233-236.